The effect of Inflation Reduction Act of 2022 on our business and the pharmaceutical industry in general is not yet known.
All entries for: Cardiovascular
March 17, 2026
Longeveron Inc
Neutral Outlook
Miami, FL
1-50 employees
On August 16, 2022, the Inflation Reduction Act of 2022 was passed, which among other things, allows for CMS to negotiate prices for certain single-source drugs and biologics reimbursed under Medicare Part B and Part D, beginning with ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 Part D drugs in 2027, 15 Part B or Part D drugs in 2028, and 20 Part B or Part D drugs in 2029 and beyond.
Disease Area: Cardiovascular, Rare Diseases
Drug Type: Biologic
February 3, 2026
Amgen Inc
Negative Outlook
Thousand Oaks, CA
10,000+ employees
Other operating expenses for the full year included Otezla® intangible asset impairment charges of $1.2 billion, following the selection of Otezla® for Medicare price setting, as part of the Inflation Reduction Act (IRA).
Disease Area: Cardiovascular, Hematology, Metabolic Diseases, Oncology, Rare Diseases
Drug Type: Biologic, Small Molecule
August 19, 2025
Windtree Theraputics INC
Neutral Outlook
Warrington, Pennsylvania
1-50 employees
…recently enacted and future legislation, including but not limited to, the Inflation Reduction Act of 2022, regarding the healthcare system in the U.S. or the healthcare systems in foreign jurisdictions;
Disease Area: Cardiovascular, Oncology, Respiratory Diseases
Drug Type: Small Molecule